afamelanotide

01/01/2021 - "Larger scale studies are needed to confirm the efficacy of afamelanotide in treating dermatologic conditions beyond erythropoietic protoporphyria, and further research should focus on determining the safety, efficacy, and optimal dosing of afamelanotide for pediatric patients.J Drugs Dermatol. "
01/01/2020 - "Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice."
03/05/2013 - "In a recent trial, afamelanotide administered as controlled release implants protected erythropoietic protoporphyria (EPP) patients from sunlight induced phototoxic skin reactions. "
10/13/2023 - "Erythropoietic Protoporphyria and Afamelanotide: A Patient's Perspective."
09/01/2023 - "Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. "

01/01/2013 - "We propose that afamelanotide represents a novel and potentially effective treatment for vitiligo. "
03/01/2015 - "Indications and limitations of afamelanotide for treating vitiligo-reply."
03/01/2015 - "Indications and limitations of afamelanotide for treating vitiligo."
01/01/2015 - "Comparison between Fitzpatrick SPTs showed patients with SPTs IV to VI in the combination therapy group had improvement in the Vitiligo Area Scoring Index at days 56 and 84 (P < .05); no significant difference was noted in patients with SPT III. A combination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB-UV-B monotherapy. "
01/01/2013 - "The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo."

09/01/2010 - "Meanwhile, the regulated α-MSH analogue afamelanotide (Clinuvel Pharmaceuticals Ltd, Melbourne, Australia) is showing promise for its photoprotective potential, and is undergoing phase II and III clinical trials in people with photosensitivity disorders and those prone to nonmelanoma skin cancer. "

09/01/2010 - "Meanwhile, the regulated α-MSH analogue afamelanotide (Clinuvel Pharmaceuticals Ltd, Melbourne, Australia) is showing promise for its photoprotective potential, and is undergoing phase II and III clinical trials in people with photosensitivity disorders and those prone to nonmelanoma skin cancer. "

01/01/2022 - "In EPP patients afamelanotide treatment is associated with increased white light exposure during spring, and overall less pain. "
01/01/2021 - "Previously, afamelanotide treatment was studied using time to pain or time outside as primary outcome measures. "
07/02/2015 - "Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria. "
01/01/2020 - "The effectiveness of afamelanotide treatment in patients with erythropoietic protoporphyria (EPP) in clinical practice who experience pain after light exposure that substantially impairs quality of life is unknown. "
04/01/2016 - "Compared with placebo, afamelanotide treatment enabled patients to spend more time in direct sunlight without pain and increased the time to the appearance of the first symptoms of phototoxicity provoked by a standardized light source. "